Harmonizing the Pre-Analytical Factors to Promote Compatibility of Using ctDNA as a Surrogate Endpoint in Advanced Tumors

Time: 12:00 pm
day: Day Two Track A AM


  • Correlating ctDNA changes after treatment with long term outcome
  • Standardizing ctDNA molecular response rate which may be used in randomized studies
  • Refining the potential of ctDNA as a surrogate endpoint by advising future directions